Abstract
Emerging lines of evidence suggest that in addition to growth factors, the process of colorectal tumorigenesis may also be driven by the upregulation of the inducible form of cyclooxygenase-2 (COX-2), an enzyme responsible for the conversion of arachidonic acid to PGEs. The present study was undertaken to investigate the expression and activation of the HER family members, and to explore the regulation of COX-2 expression by the HER2 pathway in human colorectal cancer cells. Here, we report that human colorectal cancer cell lines express abundant levels of HER2 and HER3 receptors, and are growth-stimulated by recombinant neu-differentiation factor-beta 1 (NDF). NDF-treatment of colorectal cancer cells was accompanied by increased tyrosine phosphorylation and heterodimerization of HER3 with HER2. In addition, we demonstrated that HER2 and HER3 receptors in colorectal cancer cells are constitutively phosphorylated on tyrosine residues and form heterodimeric complexes in the absence of exogenous NDF. Inhibition of HER2/HER3 signaling by an anti-HER3 mAb against the ligand binding site resulted in a decrease in the levels of constitutively activated HER2/HER3 heterodimers, and the unexpected reduction of COX-2 expression. Activation of the HER2/HER3 pathway by NDF induced the activation of COX-2 promoter, expression of COX-2 mRNA, COX-2 protein and accumulation of prostaglandin E2 in the culture medium. Finally, we demonstrated that NDF promotes the ability of colorectal cancer cells to survive in an extracellular matrix milieu, such as Matrigel, and also to invade through a 8 μm porous membrane. These biological activities of NDF and its stimulation of cell proliferation are blocked by a specific inhibitor of COX-2. Taken together, our findings provide the first biochemical evidence of a possible role of the COX-2 pathway in the mitogenic action of NDF in colorectal cancer cells where it may be constitutively upregulated due to the autocrine/paracrine activation of HER2/HER3 heterodimers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- NDF:
-
recombinant neu-differentiation factor-beta 1
- COX-2:
-
cyclooxygenase-2
- mAb:
-
monoclonal antibody
- PGE2:
-
prostaglandin E2
References
Adam L, Crepin M, Lelong J, Spanakis E and Israel L. . 1994 Int. J. Cancer 59: 262–268.
Alroy I and Yarden Y. . 1997 FEBS Lett. 410: 83–86.
Anzano M, Rieman D, Pritchett W, Bowen-Pope D and Grieg R. . 1989 Cancer Res. 49: 2898–2904.
Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo X, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCosse JJ and Bertagnolli MM. . 1996 Cancer Res. 56: 2556–2560.
Brattain MG, Levine AE, Chakrabarty S, Yeoman LC, Willson JKV and Long B. . 1984 Cancer Metast. Rev. 3: 177–191.
Carraway III KL, Soltoff SP, Diamonti AJ and Cantley LC. . 1995 J. Biol. Chem. 270: 7111–7116.
Carraway III KL and Cantley LC. . 1994 Cell 78: 5–8.
Chiu C, McEntee MF and Whelan J. . 1997 Cancer Res. 57: 4267–4273.
Chen Q, Miyaura C, Higashi S, Murakami M, Kudo I, Saito S, Hiraide T, Shibasaki Y and Suda I. . 1997 J. Biol. Chem. 272: 5952–5958.
Chen X, Levkowitz G, Tzabart E, Karunagaran D, Lavi S, Ben-Baruch N, Leitner O, Ratzkin BJ, Bacus SS and Yarden Y. . 1996 J. Biol. Chem. 271: 7620–7629.
Ciardiello F, Kim N, Saeki T, Dono R, Persico MG, Plowman GD, Garrigues J, Radke S, Todaro GJ and Salomon DS. . 1991 Proc. Natl. Acad. Sci. USA 88: 7792–7796.
Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, Chinery R, Kirkland SC, DuBois RN, Jetton TL and Morrow JD. . 1997 Proc. Natl. Acad. Sci. USA 94: 657–662.
Coffey R, Goustin A, Soderquiat S, Shipley G, Wolfshohl J, Carpenter G and Moses H. . 1987 Cancer Res. 47: 4590–4594.
DuBois RN, Radhika A, Reddy BS and Entingh AJ. . 1996 Gastroenterology 110: 1259–1262.
DuBois RN, Awad J, Morrow J, Roberts II LJ and Bishop PR. . 1994 J. Clin. Invest. 93: 493–498.
Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and DuBois RN. . 1994 Gastroenterology 107: 1183–1188.
Fanger BO, Stephens JE and Staros JV. . 1989 FASEB J. 3: 71–75.
Granstrom E and Kindahl H. . 1978 Adv. Prostagland. Thromb. Res. 5: 119.
Graus-Porta D, Beerli RR, Daly JM and Hynes NE. . 1997 EMBO J. 16: 1647–1655.
Guy PM, Platko JV, Cantley LC, Cerione RA and Carraway III KL. . 1994 Proc. Natl. Acad. Sci. USA 91: 8132–8136.
Horan T, Wen J, Arakawa T, Liu NL, Brankow D, Hu S, Ratzkin B and Philo JS. . 1995 J. Biol. Chem. 270: 24604–24608.
Hynes NC and Stern DF. . 1994 Biochim. Biophys. Acta. 1198: 165–184.
Kapitanovic S, Radosevic S, Kapitanovic M, Andelinovic S, Ferencic Z, Tavassoli M, Primorac D, Sonicki Z, Spaventi S, Pavelic K and Spaventi R. . 1997 Gastroenterology 112: 1103–1113.
Keating MT and Williams LT. . 1988 Science 239: 914–916.
Kumar R, Shepard HM and Mendelsohn J. . 1991 Mol. Cell. Biol. 11: 979–986.
Kumar R, Mandal M, Ratzkin BJ, Liu N and Lipton A. . 1996 J. Cell. Biochem. 239: 914–916.
Kumar R and Atlas I. . 1992 Proc. Natl. Acad. Sci. USA 89: 6599–6603.
Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, White RL and Prescott SM. . 1996 Proc. Natl. Acad. Sci. USA 93: 4816–4820.
Lupu R, Cardillo M, Harris L, Hijazi M and Rosenberg K. . 1995 Cancer Biol. 6: 135–145.
Mandal M, Adam L, Mendelsohn J and Kumar R. . 1998 Oncogene In Press.
Mandal M, Wu X and Kumar R. . 1997 Carcinogenesis 18: 229–232.
Mandal M, Maggirwar SB, Sharma N, Kaufmann SH, Sun S and Kumar R. . 1996 J. Biol. Chem. 271: 30354–30359.
Martin TE, Barghusen SC, Leser GP and Spear PG. . 1987 J. Cell. Biol. 105: 2069–2082.
Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF and Taketo MM. . 1996 Cell 87: 803–809.
Pinkas-Kramarski R, Soussan L, Waterman H, Levkowizt G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M and Yarden Y. . 1997 EMBO J. 15: 2452–2467.
Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ and Yarden Y. . 1996 J. Biol. Chem. 271: 19029–19032.
Prescott SM and White RL. . 1996 Cell 87: 783–786.
Rajkumar J, Goden CSR, Lemoine NR and Gullick WJ. . 1993 J. Pathol. 170: 271–278.
Reidel H, Massoglia S, Schlessinger J and Ullrich A. . 1988 Proc. Natl. Acad. Sci. USA 85: 1477–1481.
Sierke SL, Cheng K, Kim H and Koland JG. . 1997 Biochem. J. 322: 757–763.
Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD and DuBois RN. . 1997 J. Clin. Invest. 99: 2254–2259.
Smith WL, Garavito RM and DeWitt DL. . 1996 J. Biol. Chem. 271: 33157–33160.
Tsujii M and DuBois RN. . 1995 Cell 83: 493–501.
Ullrich A and Schlessinger J. . 1990 Cell 61: 203–212.
Untawale S, Zorbas MA, Hodgson CP, Coffey RJ, Gallick GE, North SM, Wildrick DM, Olive M, Blick M, Yeoman LC and Boman BW. . 1993 Cancer Res. 53: 1630–1636.
Yang J, Yu Y, Markovic B, Russell PJ and Crowe PJ. . 1997 Anticancer Res. 17: 1023–1026.
Wen D, Peles E, Cupples R, Suggs SF, Bacus SS, Luo Y, Trail G, Hu S, Silbiger R, Levy R, Koski RA, Lu SH and Yarden Y. . 1992 Cell 69: 559–572.
Zhang K, Sun J, Liu N, Wen D, Chang D, Thomason A and Yoshinaga SK. . 1996 J. Biol. Chem. 271: 3884–3890.
Acknowledgements
We thank Steve Prescott for providing the COX-2 luciferase plasmid, MG Brattain for FET cells, and Mien-Chie Hung for NDF cDNA. This study was supported in-part by the American Institute for Cancer Research grant 96A077, the National Institute of Health grant CA65746, and new research program funds from The UTMDACC (RK).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vadlamudi, R., Mandal, M., Adam, L. et al. Regulation of Cyclooxygenase-2 pathway by HER2 receptor. Oncogene 18, 305–314 (1999). https://doi.org/10.1038/sj.onc.1202307
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202307
Keywords
This article is cited by
-
Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress
Stem Cell Research & Therapy (2022)
-
Role of Cyclooxygenase 2 (COX-2) in Prognosis of Breast Cancer
Indian Journal of Surgical Oncology (2014)
-
Effects of ectopic HER-2/neu gene expression on the COX-2/PGE2/P450arom signaling pathway in endometrial carcinoma cells: HER-2/neu gene expression in endometrial carcinoma cells
Journal of Experimental & Clinical Cancer Research (2013)
-
Synthesis and biological evaluation of new benzo-thieno[3,2-d]pyrimidin-4-one sulphonamide thio-derivatives as potential selective cyclooxygenase-2 inhibitors
Molecular Diversity (2013)
-
Identification of MAGI1 as a tumor-suppressor protein induced by cyclooxygenase-2 inhibitors in colorectal cancer cells
Oncogene (2012)